Filing Flows › Comparisons › EQ vs ABCL
Equillium vs AbCellera Biologics: EQ and ABCL compared
Equillium is the larger company: $4.4M of revenue in its latest quarter (Q4 2024) against $4.0M for AbCellera Biologics (Q2 2026). Equillium is growing faster (-52% against -76% a year earlier).
Where the money goes: EQ and ABCL
Equillium (EQ) · Q4 2024
Equillium, Q4 2024: revenue $4.4M (-52% year over year), operating margin -107.0%, net loss $5.8M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
AbCellera Biologics (ABCL) · Q2 2026
AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year), net loss $55.4M, operating cash flow $25.9M. The chart follows the revenue to costs, profit and cash.
| Equillium (EQ) | AbCellera Biologics (ABCL) | |
|---|---|---|
| Latest quarter | Q4 2024 | Q2 2026 |
| Revenue | $4.4M | $4.0M |
| Revenue growth, Y/Y | -52% | -76% |
| Operating margin | -107.0% | n/m |
| Net earnings | −$5.8M | −$55.4M |
| Net margin | -131.9% | — |
| Operating cash flow | −$3.3M | $25.9M |
| Free cash flow | — | $23.8M |
| Market value | — | $3.8B |
| Analysts’ mean target | — | $17.17 |
Where the revenue comes from
AbCellera Biologics
- Research fees: $3.9M (96%)
- Licensing and royalty revenue: $149K (4%)
Questions
Which is bigger, Equillium or AbCellera Biologics?
Equillium is the larger company: $4.4M of revenue in its latest quarter (Q4 2024) against $4.0M for AbCellera Biologics (Q2 2026).
Is Equillium or AbCellera Biologics growing faster?
Equillium is growing faster (-52% against -76% a year earlier).
More: Equillium earnings · how Equillium makes money · AbCellera Biologics earnings · how AbCellera Biologics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 27, 2025; 10-Q filed Aug 5, 2026). Fiscal quarters can end on different dates. Not investment advice.